All In Biotech

Drug Trial Radar · NCT01106586

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Last checked: Nov 19, 2026Latest source record: Nov 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 708 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

708

Actual

Start

Apr 2010

Primary completion

Sep 2011

Study completion Sep 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI \[GS-9350\])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus ritonavir-boosted atazanavir (ATV/r) plus the standard of care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF (Truvada®). ATV/r + FTC/TDF was selected as the active comparator for this study as it is a preferred protease inhibitor-based regimen in guidelines for the treatment of HIV-1 infected, antiretroviral treatment-naive adults.

Conditions

  • HIV
  • HIV Infections

Interventions

  • StribildDrug

    Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily

  • ATVDrug

    Atazanavir 300 mg capsule administered orally once daily

  • RitonavirDrug

    Ritonavir (RTV; /r) 100 mg tablet administered orally once daily

  • FTC/TDFDrug

    FTC/TDF 200/300 mg tablet administered orally once daily

  • Stribild PlaceboDrug

    Placebo to match Stribild administered orally once daily

  • ATV PlaceboDrug

    Placebo to match ATV administered orally once daily

  • RTV PlaceboDrug

    Placebo to match RTV administered orally once daily

  • FTC/TDF PlaceboDrug

    Placebo to match FTC/TDF administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48Time frame: Week 48

Locations

146 sites in 17 countries. Site status is shown where the registry gives one.

  • Spectrum Medical Group

    Phoenix, Arizona

  • Health for Life Clinic PLLC

    Little Rock, Arkansas

  • AHF Research Center

    Beverly Hills, California

  • CSI Clinical Trials, Inc.

    Costa Mesa, California

  • Apex Research, LLC

    Denver, California

  • Kaiser Permanente Hospital

    Hayward, California

  • Living Hope Clinical Foundation

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Los Angeles Gay and Lesbian Center DBA Jeffrey Goodman Special Care Clinic

    Los Angeles, California

  • Peter J Ruane, MD, Inc

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Anthony Mills MD Inc

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • Alameda County Medical Center

    Oakland, California

  • East Bay AIDS Center

    Oakland, California

  • Stanford University

    Palo Alto, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Metropolitan Medical

    San Francisco, California

  • Kaiser Permanente Medical Center, Clinical Trials Unit

    San Francisco, California

  • National Jewish Health

    Denver, Colorado

  • Yale University HIV Clinical Trials Program

    New Haven, Connecticut

  • The Stamford Hospital

    Stamford, Connecticut

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • Whitman Walker Clinic

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • Broward Health/Comprehensive Care Center

    Fort Lauderdale, Florida

  • Gary J. Richmond,M.D., P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • IDOCF/ ValueHealthMD, LLC

    Orlando, Florida

  • University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • Treasure Coast Infectious Disease Consultants

    Vero Beach, Florida

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.